Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
CC transcript
|
|
PALISADE BIO, INC. (CUR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/16/2020 |
8-K
| Quarterly results |
| 08/14/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results |
| 11/16/2018 |
8-K
| Quarterly results |
| 08/15/2018 |
8-K
| Quarterly results |
| 03/23/2017 |
8-K
| Form 8-K - Current report |
| 08/11/2016 |
8-K
| Form 8-K - Current report |
| 05/12/2016 |
8-K
| Quarterly results |
| 03/14/2016 |
8-K
| Form 8-K - Current report |
| 11/10/2015 |
8-K
| Quarterly results|
Docs:
|
"Neuralstem Reports Third Quarter 2015 Financial Results Adds Depth to Management Team with Appointment of Industry Veterans as Second Asset Advances towards Phase 2 GERMANTOWN, MD, November 9, 2015 -- Neuralstem, Inc. a biopharmaceutical company leveraging its unique human neural stem cell-derived platform to identify and develop novel neurogenic therapies for diseases of the central nervous system , today reported its financial results and business update for the three and nine months ended September 30, 2015. Neurogenic Oral, Small Molecule Program with NSI-189 – Advancing to Phase 2. · NSI-189 Major Depressive Disorder Program: Neuralstem filed its Phase II clinical trial protocol for the treatment of MDD with the FDA in September, 2015. Maurizio Fava, M.D., Slater Family Profess..." |
|
| 08/10/2015 |
8-K
| Quarterly results|
Docs:
|
"Neuralstem Reports Second Quarter 2015 Financial Results GERMANTOWN, MD, August 10, 2015 -- Neuralstem, Inc. a biopharmaceutical company developing neural stem cell-derived small molecule and cell therapy treatments for central nervous system diseases, reported its financial results and business update for the three and six months ended June 30, 2015. Neurogenic Small Molecule Program · NSI-189 Phase II in Major Depressive Disease : Neuralstem is developing regulatory and clinical plans for a multicenter, Phase II clinical trial of NSI-189 for the treatment of MDD. Maurizio Fava, M.D., Slater Family Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital will be the principal investigator. The study is anticipated to enroll approximately 200 patients and ex..." |
|
| 05/08/2015 |
8-K
| Quarterly results|
Docs:
|
"Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update GERMANTOWN, MD, May 8, 2015 -- Neuralstem, Inc. a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported its financial results for the three months ended March 31, 2015 and provided a business and clinical update. “Neuralstem made substantial clinical progress this quarter in both our cell therapy and small molecule programs. We announced positive top-line safety data and encouraging secondary efficacy data for our Phase II ALS clinical trial, and look forward with anticipation to the release of the comprehensive data and analysis,” said Richard Garr, Neuralstem CEO. “Additionally, as we be..." |
|
| 03/16/2015 |
8-K
| Quarterly results|
Docs:
|
"NEURALSTEM REPORTS FISCAL 2014 FOURTH QUARTER FINANCIAL AND YEAR-END BUSINESS RESULTS GERMANTOWN, MD, March 16, 2015 -- Neuralstem, Inc. today reported its financial results for the fourth quarter and year ended December 31, 2014. “Neuralstem has progressed into a clinical development stage company focused on the central nervous system ,” said Richard Garr, Neuralstem President and CEO. “During 2014 we added two established industry leaders as Independent Directors, Catherine Angell Sohn, Pharm.D. and Sandford Drexel Smith. Dr. Sohn is the former Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline. Mr. Smith is the former Executive Vice President of Genzyme Corporation. The Company moved forward two lead clinical assets: our sm..." |
|
| 11/07/2014 |
8-K
| Quarterly results |
| 08/08/2014 |
8-K
| Quarterly results |
| 05/12/2014 |
8-K
| Quarterly results |
| 03/10/2014 |
8-K
| Quarterly results|
Docs:
|
"NEURALSTEM ANNOUNCES 2013 FINANCIAL RESULTS ROCKVILLE, MD, March 10, 2014 — Neuralstem, Inc. today provided an update on its clinical trials program and reported its 2013 financial results for the year ended December 31, 2013. “2013 was an exciting year for advancement in our NSI-566 cell therapy clinical programs,” said Karl Johe, PhD, Neuralstem’ s Chairman of the Board and Chief Scientific Officer. “Our Phase II ALS trial commenced in September, with increased dosing levels of our spinal cord cells towards what we expect to be the maximum safe therapeutic dose for the final cohort in this trial. At the close of 2013, we expanded our NSI-566 programs globally with the dosing of the first patient in our ischemic stroke trial in China. We also filed our IND to treat acute spinal cord injur..." |
|
| 11/13/2013 |
8-K
| Quarterly results |
| 08/09/2013 |
8-K
| Form 8-K - Current report |
| 05/10/2013 |
8-K
| Form 8-K - Current report |
| 03/15/2013 |
8-K
| Form 8-K - Current report |
| 11/09/2012 |
8-K
| Form 8-K - Current report |
| 08/10/2012 |
8-K
| Form 8-K - Current report |
| 05/09/2012 |
8-K
| Quarterly results|
Docs:
|
"NEURALSTEM REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS AND CLINICAL UPDATE ROCKVILLE, Maryland, May 9, 2012 – Neuralstem, Inc. today reported its financial results for the three months ended March 31, 2012 and provided a business and clinical update. “In the first Quarter of 2012, we entered the final cohort of our Phase I clinical trial in ALS at Emory University Hospital. We are encouraged with the recent approval by the FDA to amend the trial protocol to bring back previously transplanted patients for additional dosing. These patients, who have each received ten lumbar injections earlier in the trial, may now receive an additional five cervical injections. These three patients in our ALS Phase I trial will become the first patients to receive neural stem cell injection...",
"NEURALSTEM UPDATES ALS STEM CELL TRIAL PROGRESS FDA PERMITS ADDITIONAL DOSING OF RETURN PATIENTS ROCKVILLE, MD, May 8, 2012 — Neuralstem, Inc. announced that the Federal Drug Administration has approved the return of three patients from earlier cohorts in its ongoing Phase I safety trial to treat amyotrophic lateral sclerosis with its spinal cord stem cells . These patients will be permitted to return to the trial for second treatments as the next cohort of patients, provided they meet inclusion requirements at the scheduled time. They will be the first to receive stem cell transplantation along the length of the spinal cord." |
|
| 11/10/2011 |
8-K
| Form 8-K - Current report |
| 08/11/2011 |
8-K
| Form 8-K - Current report |
| 05/11/2011 |
8-K
| Form 8-K - Current report |
| 11/16/2010 |
8-K
| Form 8-K - Current report |
| 08/17/2010 |
8-K
| Form 8-K - Current report |
| 05/18/2010 |
8-K
| Form 8-K - Current report |
| 04/05/2010 |
8-K
| Form 8-K - Current report |
| 11/17/2009 |
8-K
| Form 8-K - Current report |
|
|
|